A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting

NCT07613307 · Not yet recruiting

Last updated 2026-07-12

This clinical trial is testing the medication Orforglipron (LY3502970) in adults with type 2 diabetes who fast during Ramadan to see how it affects their blood sugar levels.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 130 people Planned (estimated).

Who can join Ages 18–65 · all sexes

Timeline Started 2026-07 · est. completion 2027-05

Where 37 sites · India, Saudi Arabia, South Africa, United Arab Emirates

What this study is testing ClinicalTrials.gov NCT07613307 ↗

Description as written by the study sponsor.

The purpose of this study is to test the efficacy and safety of orforglipron in participants with T2D (type 2 diabetes) who participate in fasting during Ramadan. For each participant, the study will last up to 48 weeks with a minimum of 7 in clinic visits and 4 virtual visits.

Treatments tested

Orforglipron also known as LY3502970 Drug

Administered orally

Main thing measured	Change from Baseline in Hemoglobin A1C (HbA1c)
Sponsor	Eli Lilly and Company
Conditions studied	Diabetes Mellitus, Type 2, Diabetes Melletus, Glucose Metabolism Disorders, Metabolic Disorders, Nutritional and Metabolic Diseases, Endocrine System Diseases, Feeding Behavior, Behavior, Fasting, Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide Receptors, Receptors, G-Protein-Coupled, Receptors, Cell Surface, Membrane Proteins, Proteins, Receptors, Peptide
GLP-1 drugs	orforglipron

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07613307 ↗